Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A tangible and interactive viral model for enhancing virology education: using hepatitis B virus as a model system.

Frontiers in microbiology·2026

Same author

AI-driven drug reposition for pathogens: a new paradigm in pandemic preparedness.

Frontiers in chemistry·2026

Same author

The functions and inhibitors of protein tyrosine phosphatase B from <i>Mycobacterium tuberculosis</i>.

Frontiers in immunology·2026

Same author

Palmitoylation of CLDN12 regulated by ZDHHC7 and APT1/2 promotes hepatitis C virus entry.

Journal of virology·2026

Same author

Analysis of imported Chikungunya cases in China from 2006 to 2026.

Frontiers in microbiology·2026

Same author

Pre-zoonotic adaptation of Andes virus before spillover: Implications for cross-host and human transmission.

The Journal of infection·2026

Search research articles

Related Experiment Video

Updated: Dec 31, 2025

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Recent Progress in Vaccine Development Against Chikungunya Virus.

Shan Gao¹, Siqi Song^1,2, Leiliang Zhang¹

¹Institute of Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.

Frontiers in Microbiology

|January 11, 2020

Summary

Chikungunya fever (CHIKF) is a mosquito-borne illness with no vaccine. This review explores seven promising vaccine types, including inactivated, subunit, and nucleic acid vaccines, to combat the growing global health threat.

Keywords:

CHIKV VLP chikungunya fever chimeric vaccine live-attenuated vaccine

More Related Videos

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Related Experiment Videos

Last Updated: Dec 31, 2025

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

Published on: October 17, 2018

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Area of Science:

Virology
Immunology
Vaccinology

Background:

Chikungunya fever (CHIKF) is an acute, mosquito-borne viral infection caused by the chikungunya virus (CHIKV).
CHIKV infection presents with symptoms like fever, severe joint pain, rash, and headache, posing a significant global health challenge.
Currently, no licensed vaccine is available for CHIKV, highlighting an urgent need for effective prevention strategies.

Purpose of the Study:

To review recent advancements in the development of chikungunya virus (CHIKV) vaccines.
To categorize and discuss various promising CHIKV vaccine candidates.
To provide insights into future directions for CHIKV vaccine research and development.

Main Methods:

Literature review of recent studies on CHIKV vaccine development.
Classification of potential vaccine candidates into distinct categories.
Analysis of the progress and potential of each vaccine type.

Main Results:

Seven main types of CHIKV vaccine candidates were identified: inactivated, subunit, live-attenuated, recombinant virus-vectored, virus-like particle, chimeric, and nucleic acid vaccines.
Each vaccine type presents unique approaches and potential advantages for CHIKV prevention.
The review consolidates current research, offering a comprehensive overview of the vaccine landscape.

Conclusions:

Significant progress has been made in developing diverse CHIKV vaccine candidates.
The identified vaccine strategies offer promising avenues for future CHIKV prevention.
Further research and development are crucial to bring a licensed CHIKV vaccine to fruition.